ଏନଫୁଭିରଟାଇଡ

ଏନଫୁଭିରଟାଇଡ
Clinical data
Trade names	Fuzeon
AHFS/Drugs.com	monograph
MedlinePlus	a603023
data	EU EMA: yes; US DailyMed: Enfuvirtide;
Pregnancy; category	AU: B2 ; US: B (No risk in non-human studies) ; ;
Routes of; administration	Subcutaneous (SC)
Legal status
Legal status	AU: S4 (Prescription only) ; CA: ℞-only ; UK: POM (Prescription only) ; US: ℞-only ;
Pharmacokinetic data
Bioavailability	84.3% (SC)
Protein binding	92%
Metabolism	Liver
Elimination half-life	3.8 hours
Excretion	unknown
Identifiers
ECHA InfoCard	100.169.201
Chemical and physical data
Formula	C204H301N51O64
Molar mass	୪,୪୯୧.୯୫ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2c1cccc2)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3c[nH]c4c3cccc4)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](Cc5c[nH]c6c5cccc6)C(=O)N[C@@H](Cc7ccccc7)C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](Cc8cnc[nH]8)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc9ccc(cc9)O)NC(=O)C;
	InChI InChI=1S/C204H301N51O64/c1-20-102(15)166(253-195(310)137(75-100(11)12)239-200(315)150(93-258)251-190(305)143(82-112-90-215-95-219-112)248-203(318)167(103(16)21-2)254-196(311)138(76-101(13)14)240-201(316)151(94-259)252-204(319)168(105(18)260)255-197(312)139(221-106(19)261)78-108-45-47-113(262)48-46-108)202(317)233-131(58-68-164(280)281)178(293)228-130(57-67-163(278)279)182(297)250-149(92-257)198(313)232-125(52-62-155(210)266)179(294)245-145(84-157(212)268)191(306)229-124(51-61-154(209)265)175(290)224-122(49-59-152(207)263)173(288)226-126(53-63-159(270)271)176(291)222-120(43-31-33-69-205)172(287)244-144(83-156(211)267)192(307)231-127(54-64-160(272)273)177(292)225-123(50-60-153(208)264)174(289)227-128(55-65-161(274)275)180(295)235-134(72-97(5)6)185(300)237-133(71-96(3)4)184(299)230-129(56-66-162(276)277)181(296)236-135(73-98(7)8)187(302)247-147(86-165(282)283)194(309)223-121(44-32-34-70-206)171(286)241-140(79-109-87-216-117-40-28-25-37-114(109)117)183(298)220-104(17)170(285)249-148(91-256)199(314)238-136(74-99(9)10)186(301)242-142(81-111-89-218-119-42-30-27-39-116(111)119)189(304)246-146(85-158(213)269)193(308)243-141(80-110-88-217-118-41-29-26-38-115(110)118)188(303)234-132(169(214)284)77-107-35-23-22-24-36-107/h22-30,35-42,45-48,87-90,95-105,120-151,166-168,216-218,256-260,262H,20-21,31-34,43-44,49-86,91-94,205-206H2,1-19H3,(H2,207,263)(H2,208,264)(H2,209,265)(H2,210,266)(H2,211,267)(H2,212,268)(H2,213,269)(H2,214,284)(H,215,219)(H,220,298)(H,221,261)(H,222,291)(H,223,309)(H,224,290)(H,225,292)(H,226,288)(H,227,289)(H,228,293)(H,229,306)(H,230,299)(H,231,307)(H,232,313)(H,233,317)(H,234,303)(H,235,295)(H,236,296)(H,237,300)(H,238,314)(H,239,315)(H,240,316)(H,241,286)(H,242,301)(H,243,308)(H,244,287)(H,245,294)(H,246,304)(H,247,302)(H,248,318)(H,249,285)(H,250,297)(H,251,305)(H,252,319)(H,253,310)(H,254,311)(H,255,312)(H,270,271)(H,272,273)(H,274,275)(H,276,277)(H,278,279)(H,280,281)(H,282,283)/t102-,103-,104-,105+,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,166-,167-,168-/m0/s1 ; Key:PEASPLKKXBYDKL-FXEVSJAOSA-N ;
(verify)

ଏନଫୁଭିରଟାଇଡ (ଇଂରାଜୀ ଭାଷାରେ Enfuvirtide), ଫୁଜୁନ୍ ଏହାର ବିକ୍ରୟ ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ଏଚଆଇଭି/ଏଡସ ରୋଗର ପ୍ରତିଷେଧ ଓ ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବ‌ହୃତ ହୁଏ ।^[୧] ଏହି ଔଷଧର ପ୍ରତିରୋଧ ଘଟିଲେ ଅନ୍ୟାନ୍ୟ ଔଷଧମାନଙ୍କ ସହିତ ଏକତ୍ର ବ୍ୟବହୃତ ହୁଏ ।^[୨] ଚର୍ମ ତଳେ ଇଞ୍ଜେକସନ ଆକାରରେ ଏହା ଦିଆଯାଏ ।^[୧]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଇଞ୍ଜେକସନ ନେଇଥିବା ସ୍ଥାନରେ ଯନ୍ତ୍ରଣା, ପ୍ରାନ୍ତୀୟ ସ୍ନାୟୁ କ୍ଷତି ଏବଂ ଓଜନ ହ୍ରାସ ହୁଏ ।^[୨] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଓଷ୍ଟିଓନେକ୍ରୋସିସ, ଯକୃତ ସମସ୍ୟା, ଆଲର୍ଜି ପ୍ରତିକ୍ରିୟା ଏବଂ ଇମ୍ୟୁନ ରିଆକ୍ଟିଭେସନ ସିଣ୍ଡ୍ରୋମ ହୋଇପାରେ ।^[୨] ^[୩] ଗର୍ଭାବସ୍ଥାରେ କ୍ଷତିର କୌଣସି ପ୍ରମାଣ ନଥିବାବେଳେ ଏହାର ବ୍ୟବହାର ଭଲ ଭାବରେ ଅଧ୍ୟୟନ କରାଯାଇ ନାହିଁ ।^[୪] ଏହା ଏକ ଏଚ.ଆଇ.ଭି ଫ୍ୟୁଜନ୍ ନିରୋଧକ ।^[୧]

୨୦୦୩ ମସିହାରେ ଆମେରିକା ଏବଂ ୟୁରୋପରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଏନଫୁଭିରଟାଇଡ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୧] ^[୨] ଯୁକ୍ତରାଜ୍ୟରେ ୨୦୨୧ ସୁଦ୍ଧା ଏହା ପିଛା ମାସକୁ ପ୍ରାୟ ୧୧୦୦ ପାଉଣ୍ଡ ଖର୍ଚ୍ଚ ହେଉଥିଲା ।^[୫] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶିର ମୂଲ୍ୟ ପ୍ରାୟ ୩୫୦୦ ଡଲାର ଅଟେ ।^[୬]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ "Enfuvirtide Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 31 July 2020. Retrieved 15 December 2021.
↑ ^୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ "Fuzeon". Archived from the original on 7 October 2021. Retrieved 15 December 2021.
↑ "DailyMed - FUZEON- enfuvirtide kit". dailymed.nlm.nih.gov. Archived from the original on 25 March 2021. Retrieved 15 December 2021.
↑ "Enfuvirtide (Fuzeon) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 30 October 2020. Retrieved 15 December 2021.
↑ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 680. ISBN 978-0857114105.
↑ "Enfuvirtide Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 31 March 2016. Retrieved 15 December 2021.

[AHFS2021-1] ୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ "Enfuvirtide Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 31 July 2020. Retrieved 15 December 2021.

[EPAR2021-2] ୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ "Fuzeon". Archived from the original on 7 October 2021. Retrieved 15 December 2021.

[PI2021-3] "DailyMed - FUZEON- enfuvirtide kit". dailymed.nlm.nih.gov. Archived from the original on 25 March 2021. Retrieved 15 December 2021.

[4] "Enfuvirtide (Fuzeon) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 30 October 2020. Retrieved 15 December 2021.

[BNF81-5] BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 680. ISBN 978-0857114105.

[6] "Enfuvirtide Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 31 March 2016. Retrieved 15 December 2021.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]